Year None2024202320222021202020192018201720162015 Feb 16 Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU) Feb 6 Regeneron Announces Investor Conference Presentations Feb 2 Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results Feb 2 Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma Jan 30 Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs Jan 25 Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE) Jan 24 Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards Jan 16 Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement Jan 5 Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024 First page « Previous page ‹ Page 1 Page 2 Page 3 Page 4 Page 5 Current page 6